WHAT WE FOUND There is currently a shortage for Levemir and for some generic Insulin Aspart and brand-name Novolog products. There are no other ongoing reported insulin shortages as of Nov. 16, 2023.

On July 15, 2025, Biocon Biologics, a fully integrated global biosimilars company and a subsidiary of Biocon Ltd., announced that the FDA has ...

WHAT WE FOUND There is currently a shortage for Levemir and for some generic Insulin Aspart and brand-name Novolog products. There are no other ongoing reported insulin shortages as of Nov. 16, 2023.

There is currently a shortage for Levemir and for some generic Insulin Aspart and brand-name Novolog products. There are no other ongoing reported insulin shortages as of Nov. 16, 2023.

WHAT WE FOUND There is currently a shortage for Levemir and for some generic Insulin Aspart and brand-name Novolog products. There are no other ongoing reported insulin shortages as of Nov. 16, 2023.

There is currently a shortage for Levemir and for some generic Insulin Aspart and brand-name Novolog products. There are no other ongoing reported insulin shortages as of Nov. 16, 2023.

There is currently a shortage for Levemir and for some generic Insulin Aspart and brand-name Novolog products. There are no other ongoing reported insulin shortages as of Nov. 16, 2023.

Three insulin products are currently in shortage, but all other insulin products are in good supply, including alternatives for the limited products.

There is currently a shortage for Levemir and for some generic Insulin Aspart and brand-name Novolog products. There are no other ongoing reported insulin shortages as of Nov. 16, 2023.